Skip to Content
Print Share

Generic Bethkis Availability

Bethkis is a brand name of tobramycin, approved by the FDA in the following formulation(s):

BETHKIS (tobramycin - solution;inhalation)

  • Manufacturer: CHIESI USA INC
    Approval date: October 12, 2012
    Strength(s): 300MG/4ML [RLD]

Has a generic version of Bethkis been approved?

No. There is currently no therapeutically equivalent version of Bethkis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bethkis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Optimized formulation of tobramycin for aerosolization
    Patent 6,987,094
    Issued: January 17, 2006
    Inventor(s): Malvolti; Chiara & Garzia; Raffaella
    Assignee(s): Chiesi Farmaceutici S.p.A.

    The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.

    Patent expiration dates:

    • September 22, 2022
      ✓ 
      Drug product
  • Optimised formulation of tobramycin for aerosolization
    Patent 7,696,178
    Issued: April 13, 2010
    Inventor(s): Malvolti; Chiara & Garzia; Raffaella
    Assignee(s): Chiesi Farmaceutici S.p.A.

    The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.

    Patent expiration dates:

    • September 22, 2022
      ✓ 
      Drug product
  • Optimised formulation of tobramycin for aerosolization
    Patent 7,939,502
    Issued: May 10, 2011
    Inventor(s): Malvolti; Chiara & Garzia; Raffaella
    Assignee(s): Chiesi Farmaceutici S.p.A.

    The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.

    Patent expiration dates:

    • June 14, 2022
      ✓ 
      Patent use: MANAGEMENT OF CYSTIC FIBROSIS PATIENTS

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Add to My Med List
Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide